WEST HAVEN, CONNECTICUT -- September 26, 2011 -- NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced that its President, Dr. Anil R. Diwan, will present at the 10th Annual NanoBusiness Conference/NanoManufacturing Summit being held at the Seaport World Trade Center in Boston, MA, today. Dr. Diwan is invited to participate in the panel on “Nanomedicine and Nanodiagnostics - Innovation, Regulation and Financing.” The panel session is scheduled for 2pm to 4pm.
He will present a summary of the nanoviricides® platform technology, the Company’s drug pipeline, its recent successes with animal studies for the Company’s influenza therapeutic FluCide™, and progress towards the initial FDA submission.
The Company has recently announced that it is working on enabling cGMP (“current Good Manufacturing Practices”) capability for producing its drug candidates. cGMP manufactured materials will be required when the Company is ready to file an Investigational New Drug (IND) application to the US FDA. The Company has recently announced that Inno-Haven, LLC, a special purpose company, has acquired a building which the Company plans to lease for its new laboratory and cGMP manufacturing pilot plant.
The Company has recently announced that it has chosen a clinical candidate, NV-INF-1, in its anti-influenza drug program (FluCide™) to develop for regulatory submissions both domestically and internationally. The Company believes that a single course therapy easily administered by a medical office is feasible for out-patients. The Company believes that in most instances no follow-on treatment would be necessary. This expectation is based on the following results from its animal studies: (1) the extremely high treatment effectiveness in inhibiting the cycle of infection, virus expansion and spread of infection and, (2) the significantly long lasting effects of the drug treatment after the drug is discontinued
The Company has also recently announced significant successes in its anti-HIV drug program, viz. HIVCide™. The best HIVCide candidate in a recent SCID-hu Thy/Liv mouse model study showed effectiveness against HIV-1 similar to a three drug HAART (highly active anti-retroviral therapy) cocktail even when HIVCide was administered at a much lower total dosage. What is more significant, this nanoviricide drug candidate continued to work to suppress HIV viral load for at least 28 days beyond last drug administration. These data along with previous similar successes in anti-HIV drug development indicate that HIVCide may provide a “functional cure” of HIV/AIDS either alone or in combination with other drugs.
Further information on this meeting can be found at the website: http://www.internano.org/nms2011/program.. The Nanomedicine panel is being chaired by Dr. Mostafa Analoui, Head of Healthcare and Life Sciences at the Livingston Group, NY.